Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | IDH1 | O75874 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112840 | 0.85 | GLA (0.63) | MAPTHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4126914 | 0.83 | GLA (0.54) | MAPTHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4126269 | 0.81 | GLA (0.58) | MAPTHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4117289 | 0.81 | GLA (0.58) | MAPTHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4104672 | 0.80 | MEN1 (0.63) | MAPTHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4112354 | 0.80 | GLA (0.54) | MAPTHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4118402 | 0.79 | MAPT (0.62) | MAPTHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4111981 | 0.78 | MAPT (0.59) | MAPTHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4105488 | 0.77 | ALDH1A1 (0.70) | MAPTHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4117340 | 0.77 | MAPT (0.56) | MAPTHTTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | MAPT 1654/4885HTT 1736/4885SMN1; SMN2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.